230 related articles for article (PubMed ID: 34296803)
21. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
22. Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
Feng X; Chen X; Peng P; Zhou H; Hong Y; Zhu C; Lu L; Xie S; Zhang S; Long L
BMC Urol; 2024 Feb; 24(1):40. PubMed ID: 38365673
[TBL] [Abstract][Full Text] [Related]
23. Nomogram predicting prostate cancer in patients with negative prebiopsy multiparametric magnetic resonance.
Chen M; Wang R; Zhang T; Zhang X; Wan Y; Fu X
Future Oncol; 2022 Apr; 18(12):1473-1483. PubMed ID: 35105154
[TBL] [Abstract][Full Text] [Related]
24. Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy naïve men.
Knaapila J; Autio V; Jambor I; Ettala O; Verho J; Kiviniemi A; Taimen P; Perez IM; Aronen HJ; Syvänen KT; Boström PJ
Scand J Urol; 2020 Feb; 54(1):7-13. PubMed ID: 31914846
[No Abstract] [Full Text] [Related]
25. Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4-20 ng/mL.
Zheng Y; Li W; Zhang Y; Zhang C; Wang J; Ge P
Sci Rep; 2022 Dec; 12(1):21895. PubMed ID: 36536031
[TBL] [Abstract][Full Text] [Related]
26. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
[TBL] [Abstract][Full Text] [Related]
27. Deep-Learning Models for Detection and Localization of Visible Clinically Significant Prostate Cancer on Multi-Parametric MRI.
Sun Z; Wu P; Cui Y; Liu X; Wang K; Gao G; Wang H; Zhang X; Wang X
J Magn Reson Imaging; 2023 Oct; 58(4):1067-1081. PubMed ID: 36825823
[TBL] [Abstract][Full Text] [Related]
28. The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging.
Kato D; Ozawa K; Takeuchi S; Kawase M; Kawase K; Nakai C; Takai M; Iinuma K; Nakane K; Kato H; Matsuo M; Suzui N; Miyazaki T; Koie T
Curr Oncol; 2021 Mar; 28(2):1294-1301. PubMed ID: 33809967
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.
Wang S; Kozarek J; Russell R; Drescher M; Khan A; Kundra V; Barry KH; Naslund M; Siddiqui MM
Eur Urol Oncol; 2024 Apr; 7(2):189-203. PubMed ID: 37640584
[TBL] [Abstract][Full Text] [Related]
30. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
[No Abstract] [Full Text] [Related]
31. Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements.
Arita Y; Akita H; Fujiwara H; Hashimoto M; Shigeta K; Kwee TC; Yoshida S; Kosaka T; Okuda S; Oya M; Jinzaki M
Eur J Radiol Open; 2022; 9():100403. PubMed ID: 35242886
[TBL] [Abstract][Full Text] [Related]
32. Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer.
Stabile A; Dell'Oglio P; Soligo M; De Cobelli F; Gandaglia G; Fossati N; Esposito A; Brembilla G; Karnes RJ; Montorsi F; Briganti A
Eur Urol Oncol; 2021 Aug; 4(4):594-600. PubMed ID: 31204312
[TBL] [Abstract][Full Text] [Related]
33. Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.
Dwivedi DK; Kumar R; Dwivedi AK; Bora GS; Thulkar S; Sharma S; Gupta SD; Jagannathan NR
J Magn Reson Imaging; 2018 May; 47(5):1227-1236. PubMed ID: 28872226
[TBL] [Abstract][Full Text] [Related]
34. Incorporation of trans-rectal color doppler flow imaging and risk-stratification nomogram reduce unnecessary prostate biopsies in suspected prostate cancer patients: a bi-centered retrospective validation study.
Guo Y; Su K; Lu M; Liu X
BMC Urol; 2023 May; 23(1):81. PubMed ID: 37138271
[TBL] [Abstract][Full Text] [Related]
35. Comparison of a Deep Learning-Accelerated vs. Conventional T2-Weighted Sequence in Biparametric MRI of the Prostate.
Tong A; Bagga B; Petrocelli R; Smereka P; Vij A; Qian K; Grimm R; Kamen A; Keerthivasan MB; Nickel MD; von Busch H; Chandarana H
J Magn Reson Imaging; 2023 Oct; 58(4):1055-1064. PubMed ID: 36651358
[TBL] [Abstract][Full Text] [Related]
36. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
37. Avoiding Unnecessary Systematic Biopsy in Clinically Significant Prostate Cancer: Comparison Between MRI-Based Radiomics Model and PI-RADS Category.
Cheng X; Chen Y; Xu H; Ye L; Tong S; Li H; Zhang T; Tian S; Qi J; Zeng H; Yao J; Song B
J Magn Reson Imaging; 2023 Feb; 57(2):578-586. PubMed ID: 35852438
[TBL] [Abstract][Full Text] [Related]
38. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
[TBL] [Abstract][Full Text] [Related]
39. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
Tosun M; Uslu H
Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
[TBL] [Abstract][Full Text] [Related]
40. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study.
Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Winther MD; Jakobsen H; Thomsen HS
JAMA Netw Open; 2018 Jun; 1(2):e180219. PubMed ID: 30646066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
